Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter R Shepherd

Showing results (91-100 of 109) with videos related to

Pageof 11
Sort By:
Bioorganic & Medicinal Chemistry|September 30, 2017
Synthesis and biological evaluation of sulfonamide analogues of the phosphatidylinositol 3-kinase inhibitor ZSTK474Swarna A Gamage, Anna C Giddens, Kit Y Tsang, et al.
Pigment Cell & Melanoma Research|June 23, 2020
Genomic and signalling pathway characterization of the NZM panel of melanoma cell lines: A valuable model for studying the impact of genetic diversity in melanomaKhanh B Tran, Gregory Gimenez, Peter Tsai, et al.
The Biochemical Journal|August 3, 2013
Phosphatidylinositol 3-phosphate 5-kinase (PIKfyve) is an AMPK target participating in contraction-stimulated glucose uptake in skeletal muscleYang Liu, Yu-Chiang Lai, Elaine V Hill, et al.
Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy|April 29, 2025
Reduced Weight Gain with Pioglitazone vs Vildagliptin in <i>CREBRF</i> rs373863828 A-allele Carriers: Insights from the WORTH TrialZanetta L L Toomata, Yannan Jiang, Rui Qian Yeu, et al.
Plos Biology|March 26, 2013
Protein kinase activity of phosphoinositide 3-kinase regulates cytokine-dependent cell survivalDaniel Thomas, Jason A Powell, Benjamin D Green, et al.
Oncotarget|May 25, 2017
Biological characterization of SN32976, a selective inhibitor of PI3K and mTOR with preferential activity to PI3Kα, in comparison to established pan PI3K inhibitorsGordon W Rewcastle, Sharada Kolekar, Christina M Buchanan, et al.
Diabetologia|August 21, 2021
The CREBRF diabetes-protective rs373863828-A allele is associated with enhanced early insulin release in men of Māori and Pacific ancestryHannah J Burden, Shannon Adams, Braydon Kulatea, et al.
Journal of Medicinal Chemistry|September 3, 2011
Synthesis and biological evaluation of novel analogues of the pan class I phosphatidylinositol 3-kinase (PI3K) inhibitor 2-(difluoromethyl)-1-[4,6-di(4-morpholinyl)-1,3,5-triazin-2-yl]-1H-benzimidazole (ZSTK474)Gordon W Rewcastle, Swarna A Gamage, Jack U Flanagan, et al.
European Journal of Medicinal Chemistry|May 7, 2013
Synthesis and biological evaluation of novel phosphatidylinositol 3-kinase inhibitors: Solubilized 4-substituted benzimidazole analogs of 2-(difluoromethyl)-1-[4,6-di(4-morpholinyl)-1,3,5-triazin-2-yl]-1H-benzimidazole (ZSTK474)Gordon W Rewcastle, Swarna A Gamage, Jack U Flanagan, et al.
Bioorganic & Medicinal Chemistry Letters|December 8, 2016
Novel pyrazolo[1,5-a]pyridines with improved aqueous solubility as p110α-selective PI3 kinase inhibitorsJackie D Kendall, Anna C Giddens, Kit Yee Tsang, et al.
Pageof 11

Showing results (91-100 of 109) with videos related to

Sort By:
Pageof 11
Bioorganic & Medicinal Chemistry|September 30, 2017
Synthesis and biological evaluation of sulfonamide analogues of the phosphatidylinositol 3-kinase inhibitor ZSTK474Swarna A Gamage, Anna C Giddens, Kit Y Tsang, et al.
Pigment Cell & Melanoma Research|June 23, 2020
Genomic and signalling pathway characterization of the NZM panel of melanoma cell lines: A valuable model for studying the impact of genetic diversity in melanomaKhanh B Tran, Gregory Gimenez, Peter Tsai, et al.
The Biochemical Journal|August 3, 2013
Phosphatidylinositol 3-phosphate 5-kinase (PIKfyve) is an AMPK target participating in contraction-stimulated glucose uptake in skeletal muscleYang Liu, Yu-Chiang Lai, Elaine V Hill, et al.
Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy|April 29, 2025
Reduced Weight Gain with Pioglitazone vs Vildagliptin in <i>CREBRF</i> rs373863828 A-allele Carriers: Insights from the WORTH TrialZanetta L L Toomata, Yannan Jiang, Rui Qian Yeu, et al.
Plos Biology|March 26, 2013
Protein kinase activity of phosphoinositide 3-kinase regulates cytokine-dependent cell survivalDaniel Thomas, Jason A Powell, Benjamin D Green, et al.
Oncotarget|May 25, 2017
Biological characterization of SN32976, a selective inhibitor of PI3K and mTOR with preferential activity to PI3Kα, in comparison to established pan PI3K inhibitorsGordon W Rewcastle, Sharada Kolekar, Christina M Buchanan, et al.
Diabetologia|August 21, 2021
The CREBRF diabetes-protective rs373863828-A allele is associated with enhanced early insulin release in men of Māori and Pacific ancestryHannah J Burden, Shannon Adams, Braydon Kulatea, et al.
Journal of Medicinal Chemistry|September 3, 2011
Synthesis and biological evaluation of novel analogues of the pan class I phosphatidylinositol 3-kinase (PI3K) inhibitor 2-(difluoromethyl)-1-[4,6-di(4-morpholinyl)-1,3,5-triazin-2-yl]-1H-benzimidazole (ZSTK474)Gordon W Rewcastle, Swarna A Gamage, Jack U Flanagan, et al.
European Journal of Medicinal Chemistry|May 7, 2013
Synthesis and biological evaluation of novel phosphatidylinositol 3-kinase inhibitors: Solubilized 4-substituted benzimidazole analogs of 2-(difluoromethyl)-1-[4,6-di(4-morpholinyl)-1,3,5-triazin-2-yl]-1H-benzimidazole (ZSTK474)Gordon W Rewcastle, Swarna A Gamage, Jack U Flanagan, et al.
Bioorganic & Medicinal Chemistry Letters|December 8, 2016
Novel pyrazolo[1,5-a]pyridines with improved aqueous solubility as p110α-selective PI3 kinase inhibitorsJackie D Kendall, Anna C Giddens, Kit Yee Tsang, et al.
Pageof 11